Medicare can pay for obesity drugs like Wegovy in certain heart patients
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles
Independent UN experts urge Yemen’s Houthis to free detained Baha'i followers
CAIRO (AP) — Human rights experts working for the United Nations on Monday urged Yemen’s Houthi rebe2024-05-21Beijing Winter Olympic Medals Pass Acceptance Test
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Care Centers in Shandong Provide Assistance and Care to Elderly People
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21National Ear Care Day Marked Across China
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Siblings trying to make US water polo teams for Paris Olympics
WALNUT, Calif. (AP) — Chase Dodd started swimming when he was just a kid. Once he began playing wate2024-05-21Maternity Leave Extended in 25 Chinese Provinces: Official
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment